FDA Inspection 1106763 — Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd.
The FDA completed an inspection of Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd. on June 14, 2019 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- June 14, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)